Gilead Bolsters Inflammatory Bowel Disease Pipeline With Promising Mid-Stage Trial Success
Gilead Sciences announced positive Phase 2 SWIFT trial results for emvistegrast, an oral treatment for active ulcerative colitis.
Share
Why It Matters
Gilead tested a new medicine for a painful gut disease. The early results looked good, so the company moves forward with confidence.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.